Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,888 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases.
Kokudo T, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Ishihara S, Makuuchi M, Kokudo N, Hasegawa K. Kokudo T, et al. Among authors: yamamoto j. Surgery. 2021 Oct;170(4):1151-1154. doi: 10.1016/j.surg.2021.04.012. Epub 2021 May 22. Surgery. 2021. PMID: 34030885 Clinical Trial.
A Resected Primary Angiosarcoma of the Pancreas Presenting Aggressive Metastatic Liver Recurrence with Uncontrollable Intra-abdominal Bleeding: a Case Report.
Igaue S, Kudo H, Kyoden Y, Hoshikawa M, Koyama K, Saitoh H, Iijima T, Motoi T, Yoshimi F, Yamamoto J. Igaue S, et al. Among authors: yamamoto j. J Gastrointest Cancer. 2022 Dec;53(4):1124-1129. doi: 10.1007/s12029-021-00727-6. Epub 2021 Oct 14. J Gastrointest Cancer. 2022. PMID: 34648135 No abstract available.
A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair-deficient/microsatellite instability-high metastatic colon cancer: A case report.
Igaue S, Okuno T, Ishibashi H, Nemoto M, Hiyoshi M, Kawasaki H, Saitoh H, Saitoh M, Akagi K, Yamamoto J. Igaue S, et al. Among authors: yamamoto j. Oncol Lett. 2022 May 17;24(1):211. doi: 10.3892/ol.2022.13332. eCollection 2022 Jul. Oncol Lett. 2022. PMID: 35720492 Free PMC article.
A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
Saiura A, Yamamoto J, Hasegawa K, Oba M, Takayama T, Miyagawa S, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Makuuchi M, Kokudo N. Saiura A, et al. Among authors: yamamoto j. Drug Discov Ther. 2014 Feb;8(1):48-56. doi: 10.5582/ddt.8.48. Drug Discov Ther. 2014. PMID: 24647158 Free article. Clinical Trial.
Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Watanabe T, Makuuchi M, Kokudo N. Hasegawa K, et al. Among authors: yamamoto j. PLoS One. 2016 Sep 2;11(9):e0162400. doi: 10.1371/journal.pone.0162400. eCollection 2016. PLoS One. 2016. PMID: 27588959 Free PMC article. Clinical Trial.
1,888 results